C5AR1 and neoplasm: Finally, it is interesting to point that the preclinical findings showing the feasibility and value of blocking C5a/C5aR1 to increase tumor-killing efficacy of checkpoint inhibitors have been the basis for the design of a phase I/II study (STELLAR-001).